Aberdeen Group’s HUTCHMED HCM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-27,236
Closed -$403K 921
2022
Q4
$403K Buy
27,236
+11,637
+75% +$127K ﹤0.01% 851
2022
Q3
$139K Buy
15,599
+5,117
+49% +$64.4K ﹤0.01% 921
2022
Q2
$133K Buy
+10,482
New +$133K ﹤0.01% 944
2022
Q1
Sell
-8,084
Closed -$284K 1007
2021
Q4
$284K Buy
8,084
+595
+8% +$19.3K ﹤0.01% 1010
2021
Q3
$274K Buy
7,489
+1,850
+33% +$72.8K ﹤0.01% 1008
2021
Q2
$221K Sell
5,639
-4,904
-47% -$142K ﹤0.01% 995
2021
Q1
$298K Sell
10,543
-2,277
-18% -$72.6K ﹤0.01% 953
2020
Q4
$410K Buy
12,820
+1,271
+11% +$39.1K ﹤0.01% 899
2020
Q3
$373K Buy
+11,549
New +$360K ﹤0.01% 877
2019
Q3
Sell
-16,500
Closed -$363K 930
2019
Q2
$363K Buy
+16,500
New +$471K ﹤0.01% 906

Other funds holding HCM

Aberdeen Group's HCM Position: Q1 2023 in Review

Aberdeen Group sold out of HUTCHMED (HCM) in Q1 2023, closing a stake of 27,236 shares — an estimated $403K sold.

Aberdeen Group first reported a position in HCM in Q2 2019 and held it in 10 quarters. The position peaked at $410K in Q4 2020. 71 funds tracked by Wall St. Rank hold HCM as of Q1 2023.

  • Aberdeen Group reported no remaining HUTCHMED position as of Q1 2023 after selling out during the quarter.
  • Aberdeen Group sold 27,236 HUTCHMED shares in Q1 2023, an estimated $403K.
  • Aberdeen Group first reported a position in HUTCHMED in Q2 2019 and held it in 10 quarters.
  • Aberdeen Group's HUTCHMED position peaked at $410K in Q4 2020.
  • 71 funds tracked by Wall St. Rank held HUTCHMED as of Q1 2023.

Based on Aberdeen Group's 13F filing for Q1 2023, filed 28 Apr 2023.